Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

1.

Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies.

Ho VT, Revta C, Richardson PG.

Bone Marrow Transplant. 2008 Feb;41(3):229-37. Epub 2007 Nov 12. Review.

PMID:
17994121
[PubMed - indexed for MEDLINE]
2.

Late-onset hepatic veno-occlusive disease post autologous peripheral stem cell transplantation successfully treated with oral defibrotide.

Shah MS, Jeevangi NK, Joshi A, Khattry N.

J Cancer Res Ther. 2009 Oct-Dec;5(4):312-4. doi: 10.4103/0973-1482.59910.

PMID:
20160371
[PubMed - indexed for MEDLINE]
Free Article
3.

Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide.

Ho VT, Linden E, Revta C, Richardson PG.

Semin Thromb Hemost. 2007 Jun;33(4):373-88. Review.

PMID:
17525895
[PubMed - indexed for MEDLINE]
4.

Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.

Corbacioglu S, Kernan N, Lehmann L, Brochstein J, Revta C, Grupp S, Martin P, Richardson PG.

Expert Rev Hematol. 2012 Jun;5(3):291-302. doi: 10.1586/ehm.12.18. Review.

PMID:
22780209
[PubMed - indexed for MEDLINE]
5.

BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.

Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A, Veys P, Potter MN; Haemato-oncology Task Force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation.

Br J Haematol. 2013 Nov;163(4):444-57. doi: 10.1111/bjh.12558. Epub 2013 Sep 17.

PMID:
24102514
[PubMed - indexed for MEDLINE]
6.

Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.

Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, Martin PL, Steinbach G, Murray KF, Vogelsang GB, Chen AR, Krishnan A, Kernan NA, Avigan DE, Spitzer TR, Shulman HM, Di Salvo DN, Revta C, Warren D, Momtaz P, Bradwin G, Wei LJ, Iacobelli M, McDonald GB, Guinan EC.

Biol Blood Marrow Transplant. 2010 Jul;16(7):1005-17. doi: 10.1016/j.bbmt.2010.02.009. Epub 2010 Feb 16.

PMID:
20167278
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Defibrotide for the prevention of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a systematic review.

Zhang L, Wang Y, Huang H.

Clin Transplant. 2012 Jul-Aug;26(4):511-9. doi: 10.1111/j.1399-0012.2012.01604.x. Epub 2012 Mar 20. Review.

PMID:
22428954
[PubMed - indexed for MEDLINE]
8.

Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF).

Kaleelrahman M, Eaton JD, Leeming D, Bowyer K, Taberner D, Chang J, Scarffe JH, Chopra R.

Hematology. 2003 Apr;8(2):91-5.

PMID:
12745658
[PubMed - indexed for MEDLINE]
9.

Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.

Qureshi A, Marshall L, Lancaster D.

Pediatr Blood Cancer. 2008 Apr;50(4):831-2. doi: 10.1002/pbc.21425.

PMID:
18286502
[PubMed - indexed for MEDLINE]
10.

Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.

Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer R, Spitzer T, Avigan D, Bearman SI, Martin PL, Kurtzberg J, Vredenburgh J, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC.

Blood. 2002 Dec 15;100(13):4337-43. Epub 2002 Aug 1.

PMID:
12393437
[PubMed - indexed for MEDLINE]
Free Article
11.

Use of defibrotide in the treatment and prevention of veno-occlusive disease.

Richardson P, Linden E, Revta C, Ho V.

Expert Rev Hematol. 2009 Aug;2(4):365-76. doi: 10.1586/ehm.09.30. Review.

PMID:
21082942
[PubMed - indexed for MEDLINE]
12.

Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy.

Haussmann U, Fischer J, Eber S, Scherer F, Seger R, Gungor T.

Haematologica. 2006 Jun;91(6):795-800.

PMID:
16769582
[PubMed - indexed for MEDLINE]
Free Article
13.

Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population.

Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC.

Blood. 1998 Aug 1;92(3):737-44. Review.

PMID:
9680339
[PubMed - indexed for MEDLINE]
Free Article
14.

Successful treatment with defibrotide for sinusoidal obstruction syndrome after hematopoietic stem cell transplantation.

Yakushijin K, Matsui T, Okamura A, Yamamoto K, Ito M, Chihara K.

Kobe J Med Sci. 2005;51(3-4):55-65.

PMID:
16444097
[PubMed - indexed for MEDLINE]
Free Article
15.

Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.

Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, Boelens JJ, Hewitt A, Schrum J, Schulz AS, Müller I, Stein J, Wynn R, Greil J, Sykora KW, Matthes-Martin S, Führer M, O'Meara A, Toporski J, Sedlacek P, Schlegel PG, Ehlert K, Fasth A, Winiarski J, Arvidson J, Mauz-Körholz C, Ozsahin H, Schrauder A, Bader P, Massaro J, D'Agostino R, Hoyle M, Iacobelli M, Debatin KM, Peters C, Dini G.

Lancet. 2012 Apr 7;379(9823):1301-9. doi: 10.1016/S0140-6736(11)61938-7. Epub 2012 Feb 23.

PMID:
22364685
[PubMed - indexed for MEDLINE]
16.

Veno-occlusive disease of the liver after hemopoietic cell transplantation.

Carreras E.

Eur J Haematol. 2000 May;64(5):281-91. Review.

PMID:
10863974
[PubMed - indexed for MEDLINE]
17.

Drug safety evaluation of defibrotide.

Richardson PG, Corbacioglu S, Ho VT, Kernan NA, Lehmann L, Maguire C, Maglio M, Hoyle M, Sardella M, Giralt S, Holler E, Carreras E, Niederwieser D, Soiffer R.

Expert Opin Drug Saf. 2013 Jan;12(1):123-36. doi: 10.1517/14740338.2012.749855. Epub 2012 Dec 10. Review.

PMID:
23228043
[PubMed - indexed for MEDLINE]
18.

Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action.

Kornblum N, Ayyanar K, Benimetskaya L, Richardson P, Iacobelli M, Stein CA.

Oligonucleotides. 2006 Spring;16(1):105-14. Review.

PMID:
16584299
[PubMed - indexed for MEDLINE]
19.

Treatment of sinusoidal obstruction syndrome with defibrotide: a single-center experience.

Sucak GT, Aki ZS, Yagcí M, Yegin ZA, Ozkurt ZN, Haznedar R.

Transplant Proc. 2007 Jun;39(5):1558-63.

PMID:
17580188
[PubMed - indexed for MEDLINE]
20.

Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study.

Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, Neumeister P, Finazzi G, Iacobelli M, Bowyer K, Prentice HG, Barbui T.

Br J Haematol. 2000 Dec;111(4):1122-9.

PMID:
11167751
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk